Abstract: Mycophenolic acid (MPA), the active moiety of both mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), serves as a primary immunosuppressant for maintaining solid organ transplants. Therapeutic drug monitoring (TDM) enhances treatment outcomes through tailored approaches. This study aimed to develop an evidence-based guideline for MPA TDM, facilitating its rational application in clinical settings. The guideline plan was drawn from the Institute of Medicine and World Health Organization (WHO) guidelines. Using the Delphi method, clinical questions and outcome indicators were generated. Systematic reviews, Grading of Recommendations Assessment, development, and Evaluation (GRADE) evidence quality evaluations, expert opinions, and patient values guided evidence-based suggestions for the guideline. External reviews further refined the recommendations. The guideline for the TDM of MPA (IPGRP-2020CN099) consists of four sections and 16 recommendations encompassing target populations, monitoring strategies, dosage regimens, and influencing factors. High-risk populations, timing of TDM, area under the curve (AUC) versus trough concentration (C₀), target concentration ranges, monitoring frequency, and analytical methods are addressed. Formulation-specific recommendations, initial dosage regimens, populations with unique considerations, pharmacokinetic-informed dosing, body weight factors, pharmacogenetics, and drug‍–‍drug interactions are covered. The evidence-based guideline offers a comprehensive recommendation for solid organ transplant recipients undergoing MPA therapy, promoting standardization of MPA TDM, and enhancing treatment efficacy and safety.

实体器官移植霉酚酸治疗药物监测循证指南

[1]ArnsW, BreuerS, ChoudhuryS, et al., 2005. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant, 19(2):199-206.

[2]BaiF, LingJ, EsoimemeG, et al., 2018. A systematic review of questionnaires about patient’s values and preferences in clinical practice guidelines. Patient Prefer Adherence, 12:2309-2323.

[3]BalshemH, HelfandM, SchünemannHJ, et al., 2011. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol, 64(4):401-406.

[4]BealJL, JonesCE, TaylorPJ, et al., 1998. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit, 20(6):685-690.

[5]BehrendM, 2001. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation. BioDrugs, 15(1):37-53.

[6]BehrendM, BraunF, 2005. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs, 65(8):1037-1050.

[7]BerganS, BrunetM, HesselinkDA, et al., 2021. Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit, 43(2):‍150-200.

[8]BlanchetB, TaiebF, ContiF, et al., 2008. Comparison of a new enzymatic assay with a high-performance liquid chromatography/ultraviolet detection method for therapeutic drug monitoring of mycophenolic acid in adult liver transplant recipients. Liver Transpl, 14(12):‍1745-1751.

[9]BrouwersMC, KhoME, BrowmanGP, et al., 2010. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ, 182(18):E839-E842.

[10]BrownNW, FranklinME, EinarsdottirEN, et al., 2010. An investigation into the bias between liquid chromatography-tandem mass spectrometry and an enzyme multiplied immunoassay technique for the measurement of mycophenolic acid. Ther Drug Monit, 32(4):420-426.

[11]BuddeK, CurtisJ, KnollG, et al., 2004. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant, 4(2):237-243.

[12]CaiMY, ZhouL, GaoDH, et al., 2023. A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019. Front Pharmacol, 14:1022134.

[13]CaponeD, TarantinoG, KadilliI, et al., 2011. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. Nephrol Dial Transplant, 26(9):3019-3025.

[14]CaragataR, WyssusekKH, KrugerP, 2016. Acute kidney injury following liver transplantation: a systematic review of published predictive models. Anaesth Intensive Care, 44(2):251-261.

[15]CattaneoD, CortinovisM, BaldelliS, et al., 2007. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol, 2(6):1147-1155.

[16]ChakrabartiK, FrameD, al AbbasM, et al., 2021. The use of mycophenolate mofetil area under the curve. Curr Opin Rheumatol, 33(3):221-232.

[17]ChenYL, YangKH, MarušicA, et al., 2017. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 166(2):128-132.

[18]CiancioG, GaynorJJ, ZarakA, et al., 2011. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. Transplantation, 91(11):1198-1205.

[19]CooperM, DeeringKL, SlakeyDP, et al., 2009. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation, 88(4):514-520.

[20]CusumanoJA, KlinkerKP, HuttnerA, et al., 2020. Towards precision medicine: therapeutic drug monitoring-guided dosing of vancomycin and β‍-lactam antibiotics to maximize effectiveness and minimize toxicity. Am J Health Syst Pharm, 77(14):1104-1112.

[21]DasguptaA, JohnsonM, 2013. Positive bias in mycophenolic acid concentrations determined by the CEDIA assay compared to HPLC-UV method: is CEDIA assay suitable for therapeutic drug monitoring of mycophenolic acid? J Clin Lab Anal, 27(1):77-80.

[22]de WinterBCM, van GelderT, MathotRAA, et al., 2009. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit, 31(5):585-591.

[23]de WinterBCM, MathotRAA, SombogaardF, et al., 2011. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol, 6(3):656-663.

[24]DenewarAA, MohamedEM, IsmaelMIM, et al., 2021. Impact of therapeutic dose monitoring of mycophenolic acid on the outcome of live-donor kidney transplant recipients‍–a prospective controlled study. Saudi J Kidney Dis Transpl, 32(1):128-136.

[25]DewidarO, LotfiT, LangendamMW, et al., 2023. Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance. BMJ Evid Based Med, 28(3):189-196.

[26]DingC, XueW, TianP, et al., 2014. Which is more suitable for kidney transplantation at the early post-transplantation phase in China ‍‍–‍‍ low dosing or standard dosing of enteric-coated mycophenolate sodium? Int J Clin Pract, 68:10-16.

[27]DöschAO, EhlermannP, KochA, et al., 2006. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Clin Ther, 28(6):893-905.

[28]DreesenE, BossuytP, MullemanD, et al., 2017. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol, 9:101-111.

[29]EckardtKU, KasiskeBL, ZeierMG, 2009. Special Issue: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant, 9(Suppl 3):‍S1-S155.

[30]EttengerR, BartoshS, ChoiL, et al., 2005. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant, 9(6):780-787.

[31]European Mycophenolate Mofetil Cooperative Study Group, 1995. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet, 345(8961):1321-1325.

[32]FengJJ, ZhangLW, ZhaoP, et al., 2015. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil. Int J Clin Pract, 69:1-7.

[33]FerreiraPCL, ThiesenFV, PereiraAG, et al., 2020. A short overview on mycophenolic acid pharmacology and pharmacokinetics. Clin Transplant, 34(8):e13997.

[34]FlechnerSM, FengJ, MastroianniB, et al., 2005. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation, 79(8):926-934.

[35]FuL, HuangZ, SongT, et al., 2014. Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, single-center cohort study in Chinese living-related kidney transplantation. Transpl Infect Dis, 16(5):760-766.

[36]GastonRS, KaplanB, ShahT, et al., 2009. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant, 9(7):1607-1619.

[37]GlanderP, SommererC, ArnsW, et al., 2010. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol, 5(3):503-511.

[38]González-RonceroFM, GentilMA, BrunetM, et al., 2005. Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. Transplant Proc, 37(9):3749-3751.

[39]González-RonceroFM, GovantesMAG, ChavesVC, et al., 2007. Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. Transplant Proc, 39(7):2176-2178.

[40]GourishankarS, HoudeI, KeownPA, et al., 2010. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol, 5(7):1282-1289.

[41]GuyattGH, Alonso-CoelloP, SchünemannHJ, et al., 2016. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol, 80:3-7.

[42]HoltDW, 2002. Monitoring mycophenolic acid. Ann Clin Biochem, 39(3):173-183.

[43]HosotsuboH, TakaharaS, ImamuraR, et al., 2001. Analytic validation of the enzyme multiplied immunoassay technique for the determination of mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatographic assay. Ther Drug Monit, 23(6):669-674.

[44]HsuCC, SandfordBA, 2007. The Delphi technique: making sense of consensus. Pract Assess Res Eval, 12(1):10.

[45]JiaYC, PengB, LiL, et al., 2017. Estimation of mycophenolic acid area under the curve with limited-sampling strategy in Chinese renal transplant recipients receiving enteric-coated mycophenolate sodium. Ther Drug Monit, 39(1):29-36.

[46]JiangYH, WangW, HuXP, et al., 2015. Mycophenolate mofetil (MMF) exposure of renal transplantation recipients in stable stage: a pharmacokinetic and pharmacodynamic study. Chin J Organ Transplant, 36(4):‍217-224 (in Chinese).

[47]JiaoLZ, DingCG, TianPX, et al., 2018. Outcomes of EC-MPS combined with low-dose tacrolimus in DCD kidney transplantation for high-risk DGF recipients. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(6):‍481-489.

[48]JungHY, LeeS, JeonY, et al., 2020. Mycophenolic acid trough concentration and dose are associated with hematologic abnormalities but not rejection in kidney transplant recipients. J Korean Med Sci, 35(24):e185.

[49]KamarN, MarquetP, GandiaP, et al., 2009. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. Ther Drug Monit, 31(4):451-456.

[50]KaplanB, GastonRS, Meier-KriescheHU, et al., 2010. Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Ther Drug Monit, 32(2):224-227.

[51]KhosroshahiHT, ShojaMM, PeyrovifarA, et al., 2009. Mycophenolate mofetil dose reduction in renal transplant recipients: a 5-year follow-up study. Transplant Proc, 41(7):2797-2799.

[52]KiangTKL, EnsomMHH, 2018. Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet, 57(5):547-558.

[53]KikuchiM, TanakaM, TakasakiS, et al., 2018. Comparison of PETINIA and LC-MS/MS for determining plasma mycophenolic acid concentrations in Japanese lung transplant recipients. J Pharm Health Care Sci, 4:7.

[54]KobashigawaJA, RenlundDG, GerosaG, et al., 2006. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant, 25(8):935-941.

[55]KocakH, YakupogluU, KaratasGU, et al., 2005. Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose. Transplant Proc, 37(7):3009-3011.

[56]KulabusayaB, VadcharavivadS, AvihingsanonY, et al., 2019. Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. Int J Clin Pharm, 41(4):1047-1055.

[57]KunickiPK, PawińskiT, BoczekA, et al., 2015. A comparison of the immunochemical methods, PETINIA and EMIT, with that of HPLC-UV for the routine monitoring of mycophenolic acid in heart transplant patients. Ther Drug Monit, 37(3):311-318.

[58]KuypersDRJ, de JongeH, NaesensM, et al., 2008. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther, 30(4):673-683.

[59]KuypersDRJ, le MeurY, CantarovichM, et al., 2010. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol, 5(2):341-358.

[60]LangoneAJ, ChanL, BolinP, et al., 2011. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation, 91(4):470-478.

[61]le MeurY, BüchlerM, ThierryA, et al., 2007. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant, 7(11):2496-2503.

[62]le MeurY, ThierryA, GlowackiF, et al., 2011. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Transplantation, 92(11):1244-1251.

[63]LeichtmanAB, 2007. Balancing efficacy and toxicity in kidney-transplant immunosuppression. N Engl J Med, 357(25):2625-2627.

[64]LiJ, ChenH, YangSG, et al., 2013. Individualized mycophenolate mofetil therapy based on monitoring of mycophenolic acid trough level in cardiac transplant recipients. Chin J Organ Transplant, 34(3):139-143 (in Chinese).

[65]LianJP, FengH, FangZY, et al., 2017. Research on results of plasma mycophenolic acid concentration detected by EMIT and HPLC in the patients after renal transplantation. J Mod Lab Med, 32(3):74-78 (in Chinese).

[66]LiuHJ, ZhangR, LiR, et al., 2020. Determination of mycophenolic acid in human plasma by LC-MS/MS and its correlation with EMIT. Chin J Clin Pharmacol, 36(22):3802-3806 (in Chinese).

[67]LiuKX, XuT, JiangXH, 2016. Correlations between adverse drug reactions and area under concentration-time curve of mycophenolate mofetil patients received kidney transplantation. Chin J Hosp Pharm, 36(8):658-661 (in Chinese).

[68]LiuS, ChenHS, GuoQ, et al., 2024. Investigation of patients’ preferences regarding therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. China Pharmacy, 35(1):90-94 (in Chinese).

[69]Lopez-SolisR, DeVeraM, SteelJ, et al., 2014. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transplant, 28(7):783-788.

[70]MendezR, 1998. FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. Transplant Proc, 30(4):1287-1289.

[71]MiuraM, NiiokaT, KatoS, et al., 2011. Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. Ther Drug Monit, 33(3):295-302.

[72]MohammadpurAH, NazemianF, AbtahiB, et al., 2008. Influence of renal graft function on mycophenolic acid pharmacokinetics during the early period after kidney transplant. Exp Clin Transplant, 6(4):276-281.

[73]MusuambaFT, RousseauA, BosmansJL, et al., 2009. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet, 48(11):745-758.

[74]MusuambaFT, MouradM, HaufroidV, et al., 2013. Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. Br J Clin Pharmacol, 75(5):1277-1288.

[75]NaTakuathung M, SakuludomkanW, KoonrungsesomboonN, 2021. The impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of mycophenolic acid: systematic review and meta-analysis. Clin Pharmacokinet, 60(10):1291-1302.

[76]NaffoujeR, GroverP, YuHY, et al., 2019. Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story. Cancers (Basel), 11(9):1346.

[77]NelsonJ, AlveyN, BowmanL, et al., 2022. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation. Pharmacotherapy, 42(8):‍599-633.

[78]NeylanJF, 1997. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation, 64(9):1277-1282.

[79]PawinskiT, KunickiPK, Sobieszczanska-MalekM, et al., 2009. A limited sampling strategy for estimating mycophenolic acid area under the curve in adult heart transplant patients treated with concomitant cyclosporine. J Clin Pharm Ther, 34(1):89-101.

[80]PawinskiT, LuszczynskaP, DurlikM, et al., 2013. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus. Ther Drug Monit, 35(6):760-769.

[81]PengWH, LiuGJ, HuangHF, et al., 2018. Short-term intensified dosage regimen of mycophenolic acid is associated with less acute rejection in kidney transplantation from donation after circulatory death. Urol Int, 101(4):443-449.

[82]PrémaudA, RousseauA, le MeurY, et al., 2004. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit, 26(6):609-619.

[83]ResztakM, SobiakJ, CzyrskiA, 2021. Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: a literature review of pediatric studies. Pharmaceutics, 13(12):1991.

[84]RibbaB, DudalS, LavéT, et al., 2020. Model-informed artificial intelligence: reinforcement learning for precision dosing. Clin Pharmacol Ther, 107(4):853-857.

[85]RomanoP, AgenaF, de Almeida Rezende EbnerP, et al., 2019. Longitudinal pharmacokinetics of mycophenolic acid in elderly renal transplant recipients compared to a younger control group: data from the nEverOld trial. Eur J Drug Metab Pharmacokinet, 44(2):189-199.

[86]RongY, PatelV, KiangTKL, 2021. Recent lessons learned from population pharmacokinetic studies of mycophenolic acid: physiological, genomic, and drug interactions leading to the prediction of drug effects. Expert Opin Drug Metab Toxicol, 17(12):1369-1406.

[87]SalibaF, RostaingL, GugenheimJ, et al., 2016. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study. Transplantation, 100(8):1705-1713.

[88]SalvadoriM, HolzerH, de MattosA, et al., 2004. Enteric coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant, 4(2):231-236.

[89]SánchezFructuoso AI, Perez-FloresI, CalvoN, et al., 2012. Limited-sampling strategy for mycophenolic acid in renal transplant recipients reciving enteric-coated mycophenolate sodium and tacrolimus. Ther Drug Monit, 34(3):298-305.

[90]SchünemannHJ, WierciochW, EtxeandiaI, et al., 2014. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ, 186(3):E123-E142.

[91]SekerciogluN, FuR, KimSJ, et al., 2021. Machine learning for predicting long-term kidney allograft survival: a scoping review. Ir J Med Sci, 190(2):807-817.

[92]ShawLM, KoreckaM, VenkataramananR, et al., 2003. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant, 3(5):534-542.

[93]ShipkovaM, SchützE, BesenthalI, et al., 2010. Investigation of the crossreactivity of mycophenolic acid glucuronide metabolites and of mycophenolate mofetil in the Cedia MPA assay. Ther Drug Monit, 32(1):79-85.

[94]SobiakJ, ResztakM, 2021. A systematic review of multiple linear regression-based limited sampling strategies for mycophenolic acid area under the concentration-time curve estimation. Eur J Drug Metab Pharmacokinet, 46(6):721-742.

[95]SommererC, GlanderP, ArnsW, et al., 2011. Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. Transplantation, 91(7):779-785.

[96]SquiffletJP, BäckmanL, ClaessonK, et al., 2001. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation, 72(1):63-69.

[97]TanakaM, KikuchiM, TakasakiS, et al., 2019. Limited sampling strategy for the estimation of mycophenolic acid and its acyl glucuronide metabolite area under the concentration-time curve in Japanese lung transplant recipients. J Pharm Pharm Sci, 22(1):407-417.

[98]TangJT, de WinterBC, HesselinkDA, et al., 2017. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. Br J Clin Pharmacol, 83(4):812-822.

[99]The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, 1996. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation, 61(7):1029-1037.

[100]TingLSL, PartoviN, LevyRD, et al., 2006. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy, 26(9):1232-1240.

[101]TodorovaEK, HuangSHS, KobrzynskiMC, et al., 2015. What is the intrapatient variability of mycophenolic acid trough levels? Pediatr Transplant, 19(7):669-674.

[102]van GelderT, VinksAA, 2021. Machine learning as a novel method to support therapeutic drug management and precision dosing. Clin Pharmacol Ther, 110(2):273-276.

[103]van GelderT, HilbrandsLB, VanrenterghemY, et al., 1999. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation, 68(2):261-266.

[104]van GelderT, SilvaHT, de FijterJW, et al., 2008. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation, 86(8):1043-1051.

[105]van GelderT, SilvaHT, de FijterH, et al., 2011. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation. Ther Drug Monit, 33(2):155-164.

[106]van HestRM, MathôtRAA, VultoAG, et al., 2004. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit, 26(6):620-625.

[107]VoglM, WeigelG, SeebacherG, et al., 1999. Evaluation of the EMIT mycophenolic acid assay from Dade Behring. Ther Drug Monit, 21(6):638-643.

[108]WangZY, HeJJ, LiuXY, et al., 2015. The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China. Immunopharmacol Immunotoxicol, 37(6):508-512.

[109]WestleyIS, SallustioBC, MorrisRG, 2005. Validation of a high-performance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma. Clin Biochem, 38(9):824-829.

[110]WestleyIS, RayJE, MorrisRG, 2006. CEDIA^® mycophenolic acid assay compared with HPLC-UV in specimens from transplant recipients. Ther Drug Monit, 28(5):632-636.

[111]WhitingPF, RutjesAWS, WestwoodME, et al., 2011. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 155(8):‍529-536.

[112]WoillardJB, LabriffeM, DebordJ, et al., 2021. Mycophenolic acid exposure prediction using machine learning. Clin Pharmacol Ther, 110(2):370-379.

[113]World Health Organization, 2014. WHO Handbook for Guideline Development, 2nd Ed. World Health Organization, Geneva, Switzerland, p.1-56.

[114]XiangHP, ZhouH, ZhangJ, et al., 2021. Limited sampling strategy for estimation of mycophenolic acid exposure in adult Chinese heart transplant recipients. Front Pharmacol, 12:652333.

[115]YabukiH, MatsudaY, WatanabeT, et al., 2020. Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. Clin Transplant, 34(12):e14088.

[116]YamadaS, ShiohiraH, UeharaH, et al., 2016. Implications of clinical mycophenolate mofetil dose according to individual body weight in Japanese renal transplant recipients. Transplant Proc, 48(1):35-41.

[117]YamaniMH, StarlingRC, GoormasticM, et al., 2000. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation, 69(11):2326-2330.

[118]YangY, ZhouPJ, XuD, et al., 2014. Reducing dosage of corticosteroid by mycophenolate acid therapeutic drug monitoring for renal allograft recipients. J Shanghai Jiaotong Univ (Med Sci), 34(10):1534-1538 (in Chinese).

[119]YaoX, HuangHF, WeiCC, et al., 2015. Limited sampling strategy for mycophenolic acid in Chinese kidney transplant recipients receiving enteric-coated mycophenolate sodium and tacrolimus during the early posttransplantation phase. Ther Drug Monit, 37(4):516-523.

[120]YeZK, Reintam BlaserA, LytvynL, et al., 2020. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ, 368:l6722.

[121]YeungJS, WangW, ChanL, 1999. Determination of mycophenolic acid level: comparison of high-performance liquid chromatography with homogeneous enzyme-immunoassay. Transplant Proc, 31(1-2):1214-1215.

[122]YinT, LiangHY, HuangQ, et al., 2023. A survey of therapeutic drug monitoring status in China. Ther Drug Monit, 45(2):151-158.

[123]YuZC, ZhangWX, ChenH, et al., 2007. Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant. Ther Drug Monit, 29(2):207-214.

[124]ZengLN, YiQS, HuangL, et al., 2022. The guideline for therapeutic drug monitoring guidelines development. J Evid Based Med, 15(3):272-283.

[125]ZengWS, ZhangCS, SongM, et al., 2018. Effect of mycophenolate mofetil and enteric-coated mycophenolate sodium on blood concentration in renal transplantrecipients. Organ Transplant, 9(6):436-440 (in Chinese).

[126]ZhangH, LiuL, LiJ, et al., 2016. The efficacy and safety of intensified enteric-coated mycophenolate sodium with low exposure of calcineurin inhibitors in Chinese de novo kidney transplant recipients: a prospective study. Int J Clin Pract, 70:22-30.

[127]ZhangHX, ShengCC, LiuLS, et al., 2019. Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus. Br J Clin Pharmacol, 85(4):746-761.

[128]ZhangJ, SunZ, ZhuZF, et al., 2018. Pharmacokinetics of mycophenolate mofetil and development of limited sampling strategy in early kidney transplant recipients. Front Pharmacol, 9:908.

[129]ZhangXN, LiH, WangW, et al., 2014. Comparison of pharmacokinetics and clinical application in patients given enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation. Chin J Organ Transplant, 35(8):464-468 (in Chinese).

[130]ZhouPJ, XuD, YuZC, et al., 2007. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. Clin Pharmacokinet, 46(5):389-401.